Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Next Previous
Trial Profile

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary) ; Aripiprazole; Haloperidol; Olanzapine; Paliperidone; Perphenazine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PRIDE
  • Sponsors Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine

    • Most Recent Events

    • 25 Sep 2023 Results of post hoc pooled analysis of NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM) assessing the efficacy and safety of paliperidone palmitate (PP) versus oral antipsychotic (OAP) treatment in adult patients diagnosed with schizophrenia (per DSM IV or DSM 5 criteria) and varying duration of illness (o to 3 years and greater than 3 years) published in the Journal of clinical psychiatry, 2023.
    • 03 Jan 2018 Results presented in a Johnson & Johnson Media Release.
    • 03 Jan 2018 According to a Janssen Pharmaceuticals media release, the U.S. FDA approved the inclusion of real-world data from this study in the INVEGA SUSTENNA label.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top